GT Biologics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GT Biologics - overview
Established
2008
Location
Aberdeen, Scotland, UK
Primary Industry
Biotechnology
About
Based in Aberdeen, UK, and founded in 2008 by CEO Denise Kelly, GT Biologics provides medicine based on the potent immune-regulating properties for novel bacterial isolates derived from the healthy human gut. In November 2012, GT Biologics raised GBP 450,000 funding from Aquarius Equity Partners. The company's product lines include Live Biotherapeutics (LBPs), Thetanix, and Rosburix. The company offers live biotherapeutics and disease information such as autoimmune disease, inflammatory bowel disease, paediatric crohn's disease, multiple sclerosis, and diabetes.
Current Investors
Aquarius Equity Partners
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.gt-biologics.com
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
GT Biologics - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (3,062,623) | (6,101,949) | (7,289,003) | (13,817,191) | (18,003,567) | - | - | - |
| Operating Income (USD) | (3,122,056) | (6,237,594) | (7,503,567) | (14,069,828) | (18,286,184) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | (3,122,056) | (4,385,602) | (6,119,144) | (11,057,836) | (14,658,780) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.